ZEISS receives FDA clearance for INTRABEAM 700
With its new treatment platform for intraoperative radiotherapy, ZEISS is actively shaping the medical innovation of neuro tumor therapy.
As a leading provider of medical solutions in the field of neurosurgery, ZEISS Medical Technology is also dedicated to shaping modern oncology. The company recently received 510(k) clearance from the US Food and Drug Administration (FDA) for ZEISS INTRABEAM 700 – a leading-edge platform that provides robotic-assisted precision to support intraoperative radiation therapy (IORT). With its modern digital-first architecture, ZEISS INTRABEAM 700 creates SMART workflow efficiency and provides seamless connectivity, offering real added value for neurooncology and breast cancer therapy.
You can find further information here.
